Biocon Biologics has strengthened its oncology portfolio with the development of new biosimilars aimed at expanding access to affordable cancer treatment. The move underscores the company’s focus on complex biologics as global healthcare systems seek cost-effective alternatives to high-priced innovator drugs. By leveraging advanced manufacturing capabilities and regulatory expertise, Biocon Biologics is positioning itself as a key player in the rapidly growing biosimilars market.
